Could a new drug help stroke patients recover better?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (18-80 years old) * Diagnosis of AIS due to anterior circulation (Intracranial ICA, M1 MCA) LVO with evidence of complete/near-complete revascularization following EVT (mTICI ≥2b). * Enrollment within 24 hours of reperfusion, with reperfusion occurring within 24 hours of ictus onset. * Body weight ≥ 50 kg. * Absolute reticulocyte count \>1.0 x ULN * Platelet count of \>50,000/mm³ * Absolute neutrophil count (ANC) ≥ 1500/mm³ at * Vaccination against Neisseria meningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day1 dosing, or within 14 days after EMPAVELI. Unless documented evidence exists, that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits * Women of child-bearing potential (WOCBP) must have a negative pregnancy test and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after study drug administration. * Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after study drug administration. * English/Spanish-speaking patients or legally authorized representatives (LARs). * Signed informed consent from the patient or LAR. Exclusion Criteria: * Pregnant or lactating female * Suspected pregnancy. * Renal insufficiency (GFR\<30mL/minute OR creatinine \>2 mg/dL OR need for renal replacement therapy (RRT) at time of admission). * Platelet count \< 50,000/mm³ * Absolute neutrophil count \<1500/mm³ * Baseline mRS \>2 * Presence of concomitant serious illness that would confound study, including but not limited to serious psychiatric or autoimmune disease, sepsis, or trauma. * Immunocompromised status (e.g., subjects with Human Immunodeficiency Virus \[HIV\] infection, neutropenia, complement deficiency, etc.) * Autoimmune disorder (Sjogren's Disease, Psoriasis, hediak-Higashi Syndrome) * Presence of any intracranial bleed (ICH, SAH, SDH, hemorrhagic lesion). * Active hepatic failure as defined by AST \>160 units/L and/or ALT \>180 units/L, or total bilirubin levels greater than four times normal levels (\>4.8mg/dL). * Continued use of digoxin or amlodipine (as recommended by the manufacturer due to CYP3A inhibition). * Patients with DNR orders. * Known infection at the time of admission (elevated WBC with identified infection source) * Evidence of blood dyscrasia. * Episode of fever \> 38.5 degrees Celsius during admission and prior to enrollment. * History of any clinically significant disease or disorder which, in the opinion of the Investigator, could have either put the subject at risk because of participation in the study, or interfered with interpretation of the subject's study results